Cancer

BLUE CROSS BLUE SHIELD OF MASSACHUSETTS AGAIN NAMED ONE OF TOP HEALTH PLANS IN COUNTRY FOR QUALITY AND EXPERIENCE

PPO plan awarded 5 out of 5 stars by The National Committee for Quality Assurance BOSTON, Sept. 16, 2025 /PRNewswire/…

3 months ago

datma Unveils Federated Biomarker Explorer for Health Systems, Enabling Visibility Into Data Demand Without Data Sharing or Commitment

New offering gives health systems a way to determine whether their healthcare data aligns with pharmaceutical demand before engaging or…

3 months ago

Karmanos Cancer Institute’s BMT, Hematology and Multiple Myeloma Teams Welcome New Physician

Physician specializes in stem cell transplantation for blood cancers DETROIT, Sept. 16, 2025 /PRNewswire/ -- The Barbara Ann Karmanos Cancer…

3 months ago

As New Canadian Task Force on Preventive Health Care Takes Shape, Specialists Urge Prioritization of Early Detection and Expert Input

Ottawa, Ontario--(Newsfile Corp. - September 16, 2025) - When medical screening guidelines fail to prioritize early detection, they put Canadians…

3 months ago

Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML

No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently favorable safety and tolerabilityTrial progressing…

3 months ago

The International Myeloma Foundation and IMF Nurse Leadership Board Inaugurate NLB Leadership and Mentorship Award

Honors IMF NLB Member Dr. Beth Faiman as First Recipient During the Inauguration and Awards CeremonyCLEVELAND, Ohio, Sept. 16, 2025…

3 months ago

CytoDyn to Present at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity

VANCOUVER, Washington, Sept. 16, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing…

3 months ago

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement…

3 months ago

Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments

NEW YORK, Sept. 16, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement…

3 months ago

Jyong Biotech Announces Completion of Patient Enrollment of over 700 subjects in Phase II Clinical Trial of MCS‑8 for Prostate Cancer Prevention

New Taipei City, Taiwan, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a…

3 months ago